#1 Clinical Trials Search in Europe

Deupirfenidone

A clinical trial is underway to assess the effectiveness and safety of a new drug called Deupirfenidone (LYT-100) for treating Idiopathic Pulmonary Fibrosis (IPF). This study compares Deupirfenidone to the existing treatment, pirfenidone, and a placebo. The trial aims to find the best dose of Deupirfenidone and measure its impact on lung function and quality of life for IPF patients.

Table of Contents

What is DEUPIRFENIDONE?

DEUPIRFENIDONE, also known as LYT-100, is a new drug being studied for the treatment of Idiopathic Pulmonary Fibrosis (IPF)[1]. It is an advanced version of an existing medication called pirfenidone, which is already used to treat IPF. DEUPIRFENIDONE is being developed with the hope of providing better results and fewer side effects compared to current treatments.

What condition does DEUPIRFENIDONE treat?

DEUPIRFENIDONE is specifically designed to treat Idiopathic Pulmonary Fibrosis (IPF)[1]. IPF is a serious lung disease that causes scarring (fibrosis) of the lungs. The term “idiopathic” means the cause is unknown. This scarring makes it difficult for patients to breathe and can worsen over time. IPF primarily affects older adults and can significantly impact quality of life.

Current Clinical Trial

DEUPIRFENIDONE is currently being studied in a clinical trial to evaluate its safety and effectiveness[1]. Here are some key points about the study:

  • Study Design: It’s a randomized, double-blind study, which means participants are randomly assigned to different groups, and neither the patients nor the researchers know who is receiving which treatment. This helps ensure unbiased results.
  • Participants: The study involves 240 adults aged 40 years or older who have been diagnosed with IPF but haven’t received treatment before.
  • Duration: The initial treatment period lasts for 26 weeks (about 6 months).
  • Treatment Groups: Patients are divided into four groups:
    1. DEUPIRFENIDONE 550 mg three times a day
    2. DEUPIRFENIDONE 825 mg three times a day
    3. Pirfenidone 801 mg three times a day (an existing IPF treatment)
    4. Placebo (a dummy pill with no active ingredient)
  • Long-term Extension: After the initial 26 weeks, patients have the option to continue in a long-term extension study to further evaluate the drug’s safety and effectiveness over time.

How DEUPIRFENIDONE works

While the exact mechanism of DEUPIRFENIDONE is not fully described in the provided information, it is likely similar to pirfenidone, which it is derived from[1]. Pirfenidone works by reducing inflammation and slowing down the scarring process in the lungs. DEUPIRFENIDONE is expected to work in a similar way, potentially with improved effectiveness or fewer side effects.

DEUPIRFENIDONE vs. Pirfenidone

The clinical trial is designed to compare DEUPIRFENIDONE directly with pirfenidone, an existing IPF treatment[1]. This comparison will help researchers understand if DEUPIRFENIDONE offers any advantages over the current treatment. The study includes different doses of DEUPIRFENIDONE (550 mg and 825 mg) to determine the most effective and safe dose.

Expected Outcomes

The study is measuring several important outcomes to evaluate how well DEUPIRFENIDONE works[1]:

  • Lung Function: The main measure is the rate of decline in Forced Vital Capacity (FVC), which is the amount of air a person can forcefully exhale after taking a deep breath. This helps assess how well the lungs are functioning.
  • Disease Progression: The study will track how long it takes for the disease to worsen, defined as a significant decline in lung function or death.
  • Hospitalizations and Mortality: The researchers will monitor how often patients need to be hospitalized due to breathing problems and track any deaths related to respiratory causes.
  • Quality of Life: Although not specifically mentioned, many IPF studies also consider how the treatment affects patients’ overall well-being and ability to perform daily activities.

Potential Benefits for Patients

If DEUPIRFENIDONE proves successful in this clinical trial, it could offer several benefits for IPF patients[1]:

  • Slowed Disease Progression: The primary goal is to slow down the worsening of lung function, which could help patients maintain their quality of life for longer.
  • Reduced Hospitalizations: By potentially improving lung function and slowing disease progression, DEUPIRFENIDONE might help reduce the need for hospital stays related to breathing difficulties.
  • Improved Treatment Options: If DEUPIRFENIDONE shows advantages over existing treatments like pirfenidone, it could provide patients with a more effective or better-tolerated option for managing their IPF.
  • Long-term Management: The long-term extension part of the study will help researchers understand how the drug performs over an extended period, which is crucial for a chronic condition like IPF.

It’s important to note that while these potential benefits are promising, the full results of the clinical trial are needed to confirm the effectiveness and safety of DEUPIRFENIDONE. Patients with IPF should continue to work closely with their healthcare providers to determine the best treatment options for their individual cases.

Aspect Details
Study Type Randomized, double-blind, four-arm active and placebo-controlled
Condition Idiopathic Pulmonary Fibrosis (IPF)
Drug Tested Deupirfenidone (LYT-100)
Comparators Pirfenidone, Placebo
Treatment Duration 26 weeks (with possible long-term extension)
Primary Outcome Rate of decline in Forced Vital Capacity (FVC) over 26 weeks
Secondary Outcomes Changes in FVC percent predicted, time to hospitalization or mortality, time to IPF progression
Treatment Groups Placebo, Pirfenidone 801 mg TID, LYT-100 550 mg TID, LYT-100 825 mg TID

FAQ

  • What is the purpose of this clinical trial? The purpose of this clinical trial is to evaluate the safety and effectiveness of a new drug called Deupirfenidone (LYT-100) in treating Idiopathic Pulmonary Fibrosis (IPF). The study compares Deupirfenidone to the existing treatment, pirfenidone, and a placebo.
  • How long does the trial last? The initial treatment period lasts for 26 weeks (about 6 months). After this, patients may participate in a long-term extension to evaluate the drug's tolerability and long-term safety.
  • What are the different treatment groups in the trial? There are four treatment groups in the trial: a placebo group, a group receiving pirfenidone 801 mg three times a day, and two groups receiving different doses of Deupirfenidone (550 mg and 825 mg) three times a day.
  • What is the main outcome being measured in this trial? The main outcome being measured is the rate of decline in Forced Vital Capacity (FVC) over 26 weeks. FVC is a measure of lung function that indicates how much air a person can exhale after taking a deep breath.
  • Are there any other outcomes being measured? Yes, the trial is also measuring several secondary outcomes, including changes in the percentage of predicted FVC, time to hospitalization or mortality due to respiratory causes, and time to IPF progression. The study will also evaluate other lung function tests, inflammatory biomarkers, and patient-reported outcomes.

Ongoing Clinical Trials on Deupirfenidone

  • Study on the Effects of Deupirfenidone and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Greece Romania

Glossary

  • Idiopathic Pulmonary Fibrosis (IPF): A chronic lung disease characterized by scarring (fibrosis) of the lungs, which leads to difficulty breathing. The cause is unknown, hence 'idiopathic'.
  • Deupirfenidone (LYT-100): The new drug being tested in this clinical trial for the treatment of Idiopathic Pulmonary Fibrosis.
  • Pirfenidone: An existing medication used to treat Idiopathic Pulmonary Fibrosis, which is being used as an active comparator in this study.
  • Forced Vital Capacity (FVC): A measure of lung function that represents the total amount of air a person can forcefully exhale after taking a deep breath. It's often used to assess the progression of lung diseases.
  • Placebo: A substance with no active medical effects, used as a control in testing new drugs.
  • Randomized: A method of assigning participants to different treatment groups by chance, to reduce bias in the study results.
  • Double-blind: A study design where neither the participants nor the researchers directly involved know which treatment each participant is receiving.
  • TID: An abbreviation for 'three times a day', referring to how often a medication is taken.
  • Biomarkers: Measurable indicators in the body that can be used to assess the presence or progress of a disease or the effects of a treatment.

References